Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM, a rare, life-threatening neuromuscular disease, affecting about 1 in 40-50,000 newborn males. The session will review how IPM.ai and Audentes collaborated to uncover the XLMTM patient population, with the objectives of:

  • Discovering the known and undiagnosed patient population
  • Mapping the patient journey for confirmed XLMTM patients
  • Examining frequent concomitant or misdiagnosed clinical events
  • Identifying opportunities to shorten the diagnostic journey

Our conversation will speak directly to biopharma manufacturers who are developing a therapy in rare or specialty diseases markets, including those involved in business analytics, drug development, clinical operations, new drug commercialization, and brand marketing.

Featured Speakers

Dan Fisher

Associate Principal

Dan Fisher is an Associate Principal for IPM.ai. He was previously a managing consultant with ZS Associates, where he supported biopharma organizations across the US and Europe. Dan’s experience spans a wide range of sales and marketing business issues, with a core focus in applying analytics to designing and optimizing both pre-commercial and commercial tactics. His work has been recognized with the Innovation Award at a major biotech, where he led machine learning projects in the US commercial organization. He holds an MBA from Vanderbilt University, and a BA from the University of Rochester.

Jeremy Smith

Director of Business Analytics

Jeremy has spent the last 15 years in the biotech industry, working in various roles across technical operations, process R&D, and commercial analytics. Prior to Audentes Therapeutics, he held leadership roles at Genentech and BioMarin. Jeremy has a wealth of experience delivering innovation, analytics, and strategy to help bring novel therapies to patients in need. Prior to entering the biotech industry, he was a Nuclear Engineering Officer in the US Navy.  He holds an MBA from UC Berkeley, an MS from the Naval Postgraduate School, and a BS from Tulane University.


Register now for this webinar